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NC-ABSTRACT
Managing patients with severe asthma during the coronavirus pandemic and COVID-19 is a
challenge. Authorities and physicians are still learning how COVID-19 affects people with un-
derlying diseases, and severe asthma is not an exception. Unless relevant data emerge that
change our understanding of the relative safety of medications indicated in patients with asthma
during this pandemic, clinicians must follow the recommendations of current evidence-based
guidelines for preventing loss of control and exacerbations. Also, with the absence of data that
would indicate any potential harm, current advice is to continue the administration of biological
therapies during the COVID-19 pandemic in patients with asthma for whom such therapies are
clearly indicated and have been effective. For patients with severe asthma infected by SARS-CoV-
2, the decision to maintain or postpone biological therapy until the patient recovers should be a
case-by-case based decision supported by a multidisciplinary team. A registry of cases of COVID-
19 in patients with severe asthma, including those treated with biologics, will help to address a
clinical challenge in which we have more questions than answers.
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therapies offers a promising and more personal-
ized treatment option in severe asthma, we do not
know their current safety status during the SARS-
CoV-2 pandemic. Thus, the question remains in
our clinical practice:, biologics treatment for whom
and when?WHAT DO WE KNOW ABOUT COVID-19
AND ASTHMA?
Authorities and physicians are still learning how
COVID-19 affects people with underlying diseases,
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though respiratory viruses are one of the most
common triggers for asthma exacerbations, not all
of these viruses affect patients equally. There is no
clear evidence that patients with asthma are at a
higher risk of being infected with SARS-CoV-2,1–3
although recent reports from the United States
suggest that asthma is much more common in
children and adults with COVID-19 than it was
previously reported in China and Europe.2–5
It is more likely for an asthma patient to have an
exacerbation caused by other triggers, including
allergens or other virus exposures, or even by
stopping the regular use of their prescribed medi-
cation. However, an asthma exacerbation, in gen-
eral, requires patients to visit a healthcare facility,
which now puts them at an increased risk of expo-
sure to SARS-CoV-2.6 Ongoing prospective cohort
studies (SARP, NHLBI and others) provide a
unique opportunity to examine the effects of
COVID-19 on severe asthma and potential in-
teractions with therapy, including inhaled and oral
corticosteroids, as well as targeted treatment with
biologics.
Bhatraju et al., from Seattle, USA, reported 24
patients with COVID-19, admitted to the intensive
care unit (ICU), with a mortality rate of 50%. As
coexisting disorders, 14% had asthma, corre-
sponding to three cases with mild asthma who
were treated with systemic steroids in the week
before ICU admission, as outpatients, for a pre-
sumed asthma exacerbation. These patients were
subsequently admitted to the ICU with severe
respiratory failure that required invasive mechani-
cal ventilation.7 These data, although limited, are
in accordance with previous studies during other
coronavirus outbreaks showing that systemic
steroids can be associated with a higher viral
load.8,9 Clinicians in the initial work up of a
patient with “shortness of breath”, that can
overlap COVID-19 and asthma clinical manifesta-
tions, must be aware and recognize the differences
between hypoxic respiratory failure and broncho-
spasm on physical examination to judge the need
for a course of OCS.HOW SAFE ARE INHALED
CORTICOSTEROIDS IN THE COVID-19
ERA?
In addition, therapeutic questions still exist,
including whether treatment with inhaled cortico-
steroids (ICS) influences susceptibility to SARS-
CoV-2, as well COVID-19 severity and mortality.
Unless relevant data emerge that change our
understanding of the relative safety of such medi-
cations in patients with asthma in the COVID-19
era, clinicians must follow the recommendations
of current evidence-based guidelines for prevent-
ing loss of control and exacerbations.10SHOULD BIOLOGICS FOR SEVERE
ASTHMA BE USED DIFFERENTLY IN THE
COVID-19 ERA?
Management of patients with severe asthma
during the COVID-19 pandemic may be a chal-
lenge, particularly of those on therapy with bi-
ologics. In the event they get infected with SARS-
CoV-2 and develop COVID-19, the Allergist/
Immunologist must be consulted on whether the
treatment should be maintained or withdrawn
while infection is active, and must be part of the
decision on whether biological therapies available,
which target the type 2 immune response, would
be safe in the context of COVID-19.
Based on the information available, we are
providing the current knowledge regarding the
management of severe asthma patients with bi-
ologics during the COVID-19 pandemic.
Biological therapy drugs are indicated for pa-
tients with severe asthma who are not controlled
adequately with other treatments.10 Currently
available biologics licensed as add-on treatment
for patients with severe asthma are omalizumab,
mepolizumab, benralizumab, reslizumab, and
dupilumab. These biologics target type 2
inflammatory pathways and are effective at
reducing exacerbations, maintaining control over
asthma symptoms, and reducing systemic steroid
use.11,12
Volume 13, No. 5, May 2020 3Even though biologics are generally considered
safe, especially in adults, data obtained from clin-
ical trials on long-term use are limited to one- or
two-year follow up safety registration studies.13–15
Thus, the safety profiles of these biologics in the
face of the COVID-19 pandemic cannot yet be
conclusively assessed, and two critical balanced
questions should be considered: 1.) Is there an
increased risk or not of patients using biologics to
become infected with SARS-CoV-2, and 2.) Once
asthmatic patients using biologics become infec-
ted, would the COVID-19 become more severe
because of using biologics, or would the biolog-
ical therapy help to decrease the risk of infection
and severity?
For the current approved classes of biologics,
the three anti-IL5/IL5r have their major effect tar-
geting eosinophils producing either reduction or
depletion of tissue and peripheral blood eosino-
phils. Thus, the primary question could be raised
whether eosinophils or their products (primarily
through T2 mechanisms) have any role in modi-
fying susceptibility, severity, immunity, or resis-
tance to viral infections. The primary unknown
question is whether eosinophils could be mecha-
nistically important in COVID-19 infection. There
may be some evidence of herpes zoster infection
occurring with anti-IL5 therapy in patients with
eosinophilic severe asthma16 (also, with anti-IL4/
IL13 in patients with severe atopic dermatitis),17
but COVID-19 appears to work through different
biologic pathways.
The other two biologics (anti-IgE and anti-IL4/
IL13) have their primary effects by inhibiting T2
immunity. The question is whether reduction of T2
mechanisms is beneficial or harmful in COVID-19
susceptibility or progression perhaps through ef-
fects on angiotensin-converting enzyme 2 (ACE2)
and on transmembrane protease serine 2 enzyme
(TMPRSS2). Additionally, there is some early evi-
dence that ICS therapy is associated with reduction
in ACE2 and TMPRSS2 gene expression from
sputum.18 These data may imply that other drugs
that inhibit immune function such as anti-IL-6 may
be therapeutic targets for COVID-19 infection.19
Omalizumab is a recombinant DNA-derived
humanized monoclonal antibody (mAb) that
selectively binds to human immunoglobulin E
(IgE).20 In clinical studies in allergic asthma treatedwith omalizumab, the incidence of infections such
as pharyngitis was low (1/1000 to <1/100). In
omalizumab studies including patients with
chronic spontaneous urticaria, infections such as
nasopharyngitis, sinusitis, and viral upper
respiratory tract infections were frequent (1/100
to <1/10).20 However, most of the adverse events
(AE) were mild to moderate in severity.21
Related to the viral infections, IgE plays a central
effector role in the pathophysiology of inflamma-
tory diseases of the airways.20 The PROSE study
evaluated whether treatment with omalizumab to
reduce IgE would shorten the frequency and
duration of rhinovirus illnesses in children with
allergic asthma. The authors showed that
treatment with omalizumab was able to reduce
the duration of rhinovirus infections, viral
shedding, and risk of rhinovirus illnesses.22 This
has been further studied in ex vivo models which
show a beneficial effect of omalizumab on viral
clearance and interferon levels.
Recently, Heymann et al., investigated whether
the administration of omalizumab could diminish
the asthmatic response in patients inoculated with
rhinovirus 16, in a randomized, double-blind, pla-
cebo controlled trial. The results showed that
blocking IgE with omalizumab had its strongest
effect in reducing lower respiratory tract symptoms
and improving lung function during the first four
days of the infection.23
There are no data regarding the incidence nor
severity of patients with COVID-19 receiving omali-
zumab. Physicians andother healthcare professionals
should use their best clinical judgment when evalu-
ating patients and making treatment decisions. Al-
ternatives to hospital visits exist like self-injection at
home, although this option is not availableor licensed
ineverycountry; very recently, theU.S. FoodandDrug
Administration (FDA) has approved omalizumab for
short-termhomeadministrationduring theCOVID-19
pandemic.24
Mepolizumab is a mAb directed against
interleukin-5 (IL5). Mepolizumab has a long-term
safety profile and no increase AE rate over the
study period or when compared to previous
placebo-controlled trials; the most common AEs
were respiratory tract infections (67%), headaches
(29%), worsening of asthma (27%), bronchitis
(21%), and injection-site reactions (12%).13,25
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recorded in 2% of patients, and 1% of patients
experienced a nonallergic systemic reaction. On-
treatment opportunistic infections (7%) were also
reported, none of which were parasitic
infections.13,25
Severe eosinopenia (approximately 20–40 eo-
sinophils/cubic millilitre in peripheral blood) has
been reported in early studies among patients with
COVID-19 from China, and the magnitude of
eosinopenia was related to a worse prognosis.26 It
was believed that low eosinophil counts in
peripheral blood would be related to the
infection with the SARS-CoV-2 virus itself, and not
necessarily an indicator that treatments which
reduce eosinophil counts in patients with asthma
would be associated with more severe COVID-19
disease. Interestingly, more recent studies from
China and from Italy do not further report eosi-
nopenia in patients with severe COVID-19.3,27,28
Of note, in a small phase 2 trial, patients with
PDGFRA-negative hypereosinophilic syndrome,
presenting with mean eosinophil counts of over
2300/mm3 at baseline, had a marked decrease in
both peripheral blood and tissue eosinophils 12
weeks after receiving benralizumab.29
Although the relationship of eosinophil counts and
COVID-19 is uncertain, attention is warranted to
monitor eosinophil counts among patients with
asthma, chronic rhinosinusitis with nasal polyps, and
hypereosinophilic syndromewhoareusingbiological
therapieswhich lead todecrease ineosinophil counts,
and the clinical course of COVID-19 if they get infec-
ted with the SARS-CoV-2 virus.
GSK stated that they cannot make recommen-
dations on whether interrupting therapy with
mepolizumab would impact the risk of infection
with SARS-CoV-2. In patients treated with mepoli-
zumab 100 mg subcutaneous (SC), no specific
data are currently available on the risk of infection
with SARS-CoV-2 or the severity of illness in pa-
tients infected with this virus. Physicians should use
their best clinical judgement based on their
knowledge of individual patient needs, disease
impairment and the risks vs the benefits of treat-
ment.30 Self-injection of mepolizumab permits its
administration at home thus decreasing chances of
viral exposure in the clinic.Reslizumab is a mAb against IL5, so it has the
same mechanism of action as mepolizumab. In an
open label extension of a placebo controlled
Phase III trial, the most frequently reported AEs in
both reslizumab-experienced and reslizumab-
naïve patients were asthma worsening (28% vs.
46%), nasopharyngitis (14% vs. 14%), upper respi-
ratory tract infection (10% vs. 9%), sinusitis (8% vs.
6%), headache (7% vs. 11%), and local
administration-related AEs (1%).14 The intravenous
administration of this drug must be performed in
the clinic or hospital.
Benralizumab is a humanized afucosylated mAb
against IL5 alfa receptor (IL5Ra) that induces
eosinophil apoptosis through the mechanism of
antibody-dependent cell-mediated cytotoxicity
(ADCC) involving natural killer cells, which further
induces peripheral blood eosinophil depletion.
The most common AEs were viral upper respira-
tory tract infections (14–16%) and worsening
asthma (7–10%). The most common serious
adverse events (SAEs) were worsening asthma (3–
4%), pneumonia (<1%–1%), and pneumonia
caused by bacterial infection (0–1%). No cases of
helminth infection were reported, and rates of hy-
persensitivity AEs were similar across the study
groups.15,31,32
AstraZeneca reports that currently there are no
available data regarding the risk of infection with
the SARS-CoV-2 in patients being treated with
benralizumab, nor regarding severity or progres-
sion of the disease. In the absence of any data
indicating a potential harm, it would be reasonable
to continue the administration of biologics during
the COVID-19 pandemic in patients for whom such
therapies are clearly indicated and have been
associated with efficacy.33 Self-injection is avail-
able which permits its administration at home,
decreasing in-clinic exposure.
Dupilumab is a humanized mAb directed
against the alpha-chain of the IL4 receptor (IL4Ra),
which is shared for both IL4 and IL13; hence, this
drug is able to inhibit the signalling of both ILs. The
most frequently observed adverse drug reactions
in dupilumab treatment for asthma were upper
respiratory tract infection (14%), injection site ery-
thema (13%), and headache (10%).34 SAEs were
reported in up to 8% of patients. The most
frequent SAE was pneumonia.35
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data indicating that treatment with dupilumab
could increase the risk of COVID-19 infection, and
they emphasized the following: “regarding drug
uses which are not included in the approved
product label, the safety and efficacy of such uses
have not been assessed and thus are not
approved. Regarding the prescription of the
product referenced in the enclosed materials for a
use that is different from those listed in the
approved product label, physicians should make
that decision based on their own medical judg-
ment and discretion”. Sanofi Genzyme also
included data from pivotal asthma and nasal pol-
yposis studies in the report and emphasized that
the reported rate of respiratory tract infections had
similar frequencies.36WHAT ARE THE RESPIRATORY
ORGANIZATION RECOMMENDATIONS
FOR SEVERE ASTHMA IN LIGHT OF
COVID-19?
The Global Initiative for Asthma (GINA) suggests
that people with asthma should continue to use
their inhaled asthma control medications including
ICS during the COVID-19 epidemic. Biological
therapies should be used in severe asthma pa-
tients who qualify for them, in order to limit the
need for OCS as much as possible.37
The American Academy of Allergy, Asthma &
Immunology (AAAAI) states that there is no evi-
dence that suggests immune response to COVID-
19 will be impaired in asthma patients treated
with anti-IL5 (anti-IL5Ra), anti-IL4/IL13, or anti-IgE
medications. In the absence of any data indi-
cating a potential for harm, it would be reasonable
to continue administration of biological therapies
in patients for whom such therapies are clearly
indicated and have been associated with efficacy.
AAAAI emphasizes leveraging home administra-
tion for biologics as appropriate, to mitigate the
risk of missing one or several doses. Nevertheless,
some patients may require a face-to-face interac-
tion for biologic administration.38
The American College of Allergy, Asthma and
Immunology (ACAAI) recommends that patients
with asthma remain on their medication, as none of
thesemedications, including inhaledcorticosteroidsand biologics, have been shown to increase the risk
of getting COVID-19. There is no information at this
time that biologics (for severe asthma) should be
stopped. These severe asthma patients can have an
increased risk of COVID-19 infection, and optimal
control of their chronic condition is of utmost
importance.39
The European Respiratory Society (ERS) and
European Lung Foundation (ELF) provided their
recommendation on anti IL5s; however, no infor-
mation was given on other products including
dupilumab or omalizumab. Subsequent sugges-
tions were given as answers to frequently asked
questions, and no official guidance on severe
asthma management (in light of COVID-19) was
released so far. Those suggestions were: “to not
cease or modify any asthma medication adminis-
tration due to any concerns about COVID-19; there
is a risk that doing so could hinder your asthma
control; anti-IL5 should not increase the risk of
getting COVID-19, and continuing its intake could
theoretically reduce the risk of an asthma attack in
case you were to contract the virus”.40
Several national societies, such as the British
Thoracic Society (BTS) and the Italian Society of
Allergy, Asthma & Clinical Immunology (SIAAIC),
recommend continuing the biologic treatment,
and they highlight the need for transition efforts
(from the clinic to home care). Centers must
organize themselves to promote a home-based
administration of biologics, and patients should be
advised to continue their treatments.41,42CAN WE USE BIOLOGICS IN PATIENTS
WITH ASTHMA UNDER TREATMENT FOR
COVID-19?
Worldwide, there has been considerable public,
social, and political attention paid to unproven treat-
ments against COVID-19. These have centred on the
use of hydroxychloroquine, chloroquine, azi-
thromycin, and zinc supplements. At present no ran-
domized controlled trials have demonstrated efficacy
and no evidence-based medicine (EBM) recommen-
dations exist.43 Nonetheless these interventions
would have no theoretical interference on biologics
for patients with severe asthma.
Other randomized controlled trials (RCTs)
involving antivirals (namely remdesivir, lopinavir,
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plasma/sera, and developing humanized mono-
clonal antibodies against SARS-CoV2 infection
(including tocilizumab, an IL6 receptor antagonist)
are all under study43,44 and potentially would be
also compatible with biologics in severe asthma.IN SUMMARY.
There is no evidence suggesting that the immune
response to SARS-CoV-2 should be impaired in
asthma patients treated with biological therapies. In
the absence of data that would indicate any potential
harm, the advice is to continue the administration of
biological therapies during the COVID-19 pandemic
in patients for whom such therapies are clearly indi-
cated and have been effective.
As in the placebo controlled trials with omalizu-
mab,mepolizumab, benralizumab, reslizumab, and
dupilumab in asthmatic patients, no risk of
increased infection susceptibility, or immunosup-
pressive effect was reported to date and, in the case
of omalizumab, there is a possible anti-infectious
effect; hence, we do not need to discontinue these
treatments during the current pandemic.
Stopping biologics may lead to higher risk of
asthma exacerbations, increased OCS use, and
higher probability of emergency room access and
hospitalization that themselves represent risk fac-
tors for SARS-CoV-2 exposure/infection. Thus,
when balancing costs and benefits, discontinuing
biologic treatment is currently not recommended
for patients with severe asthma with no COVID-19.
COVID-19 has a mortality risk which is particu-
larly high in the elderly and obese, especially those
with underlying cardiovascular, respiratory and
metabolic co-morbidities.45,46 It also seems to
have greater adverse effects in particular
populations, related to race, low socioeconomic
status, co-morbidities, or differences in suscepti-
bility.4 Therefore, we should be able to precisely
evaluate and guarantee that patients with asthma
must maintain their control treatment, including
biological therapies, considering their ages, co-
morbid diseases, and specific circumstances,
namely socioeconomic status.
Until we collect more information and evidence,
for the patients with severe asthma plus co-morbidities infected by SARS-CoV-2, the decision
of maintaining or postponing biological therapy
until the patient recovers should be a case-by-case
based decision supported by a multidisciplinary
team.
A registry of cases of COVID-19 in patients
with severe asthma, including those treated with
biologics, will help to address a clinical chal-
lenge where we have more questions than
answers.
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